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Abstract: The last decade has seen considerable advances in our understanding of the 
genetic basis of skin disease, as a consequence of high throughput sequencing technologies 
including next generation sequencing and whole exome sequencing. We have now determined 
the genes underlying several monogenic diseases, such as harlequin ichthyosis, Olmsted 
syndrome, and exfoliative ichthyosis, which have provided unique insights into the structure 
and function of the skin. In addition, through genome wide association studies we now 
have an understanding of how low penetrance variants contribute to inflammatory skin 
diseases such as psoriasis vulgaris and atopic dermatitis, and how they contribute to underlying 
pathophysiological disease processes. In this review we discuss strategies used to unravel 
the genes underlying both monogenic and complex trait skin diseases in the last 10 years 
and the implications on mechanistic studies, diagnostics, and therapeutics. 
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1. Introduction 
The advent of high throughput single nucleotide polymorphism (SNP) genotyping and latterly, next 
generation sequencing (NGS) technology including whole exome sequencing (WES) have revolutionised 
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our approach to genetic diagnostics and novel gene discovery in the genodermatoses—a group of 
inherited skin disorders. 
Prior to this, technologies including linkage analysis using genome wide microsatellite panels in 
combination with candidate gene screening by PCR and Sanger sequencing have been the primary method 
for discerning new skin disease-associated loci. Successes with this approach include Hailey-Hailey 
Disease (OMIM #169600) [1], Netherton Syndrome (OMIM #256500) [2], Darier-Disease (OMIM 
#124200) [3], and Dyschromatosis symmetrica hereditaria (OMIM #127400) [4]. Candidate gene 
screening approaches have also yielded success, particularly in deciphering the keratin disorders [5]. 
However, clinical and likely genetic heterogeneity of skin diseases and the availability of DNA from 
probands only, or from small families, have hindered disease gene discovery for many disorders [6]. 
This can now be surmounted with high-density SNP homozygosity mapping for consanguineous 
recessive disorders, and in particular NGS and WES for dominant and recessive disorders, which has 
facilitated our understanding of some of the genetic make up of common diseases. 
Skin diseases are ideal for determining genotype-phenotype correlations because of the relative ease 
with which clinical and histological examination can be made. In addition, inflammatory pathways 
involved in the pathogenesis of skin diseases such as psoriasis vulgaris (PV) are relevant to a number 
of other immune-mediated diseases including inflammatory bowel disease and rheumatoid arthritis [7]. 
The genetic bases of many monogenic skin diseases have been unravelled and in this review  
we focus on examples of discoveries in cutaneous genetics, applying different strategies such as SNP 
microarray, microsatellite linkage analysis, targeted NGS and WES. Equally, it has also been informative 
in understanding the significance of de novo mutations including the unusual phenomenon of revertant 
mosaicism in the skin, where spontaneous correction of a disease-causing mutation in a somatic cell 
occurs [8]. We have also gained insights into complex trait diseases and will explore what contributions 
these have made to mechanistic insights, diagnosis and treatment of common skin diseases including 
psoriasis, atopic dermatitis (AD) (eczema), and skin cancer. 
2. Harlequin Ichthyosis 
The discovery that ABCA12 gene mutations are associated with the skin disease harlequin 
ichthyosis (HI) is an example of where SNP microarray technology was used successfully to elucidate 
the genetic locus associated with this disease [9]. 
The inherited ichthyoses are a heterogeneous group of disorders characterised by skin scaling,  
often of the whole surface, and hyperkeratosis [10]. Syndromic (affecting multiple tissues) as well as 
nonsyndromic forms of ichthyosis exist and mutations in multiple genes are associated with disease 
including TGM1 (OMIM *190195), NIPAL4 (OMIM *609383), STS (OMIM *300747), ALOX12B 
(OMIM *603741), ALOXE3 (OMIM *607206), CYP4F22 (OMIM *611495), and FLG (OMIM 
*135940) amongst others (reviewed in [10]). Autosomal recessive congenital ichthyosis (ARCI) is 
comprised of three main groups: congenital ichthyosiform erythroderma (CIE), lamellar ichthyosis 
(LI) and HI [10]. HI (OMIM #242500) is the most severe form of ichthyosis and has a high perinatal 
mortality, with babies presenting at birth with hard scale plates with deep fissures, eclabium, and 
bilateral ectropion (reviewed in [9,11]). 
Genes 2014, 5 617 
 
 
The discovery of the genetic cause of HI was hampered by availability of DNA from only affected 
family members or from small families due to the severity of the condition, thus genetic linkage 
studies were unfeasible [9]. To investigate the genetic basis of HI, Kelsell et al. (2005) [9] used  
a SNP microarray to map a block of homozygosity on chromosome 2q35 and to identify a minimal 
region between HI patients from consanguineous parents, which contained the ABCA12 gene. ABCA12 
belongs to the ATP-binding cassette (ABC) A family of transporters, some members of which have 
been implicated in lipid transport (reviewed in [12]). 
ABCA12 was a promising gene candidate for HI because patient skin displayed aberrant lipid 
distribution [9] and missense mutations in ABCA12 were already known to be associated with another 
form of ARCI, LI [13]. PCR and Sanger sequencing of the ABCA12 gene in HI patients confirmed  
that recessive mutations were associated with HI [9,14]. Mutations in ABCA12 are now known to be 
associated with all three forms of ARCI (reviewed in [10]). However, unlike for LI and CIE, in which 
largely missense ABCA12 mutations are associated with disease [13,15,16], HI is usually associated 
with loss of function gene mutations including nonsense, frameshift, and splice site mutations, which 
severely disrupt the cellular functions of ABCA12 [9,17–19]. However, there are reports of patients 
who have ABCA12 missense mutations [9,11,18,20–22]. HI patients with homozygous loss of function 
mutations have an increased risk of mortality, indicating a survival advantage for patients with compound 
heterozygous mutations [11]. 
ABCA12 is thought to transport lipids via lamellar granules where they are processed and released 
to form lipid lamellae constituting the stratum corneum in the epidermis [14,23]. A reduction in the 
number, and structural abnormalities, of lamellar granules has been observed in HI patient skin [14,24,25]. 
In addition, characterisation of HI patient skin has shown a loss of nonpolar lipids [26] and abnormal 
glucosylceramide localization [14], and experiments with patient-derived keratinocytes showed 
aberrant glucosylceramide accumulation in lamellar granules [27], which is indicative of a lipid transport 
defect as a result of loss of ABCA12 function [14,26,27]. 
Similarly, Abca12 knockout mice models [28–30] and an abca12 knockout zebrafish model [31] 
showed features of aberrant lipid transport compared to controls (reviewed in [32]). HI skin also shows 
features of premature terminal differentiation and a decreased expression of certain proteases, which 
suggests that loss of ABCA12 disrupts keratinocyte differentiation and epidermal desquamation, 
resulting in the formation of an aberrant epidermal barrier [26]. 
Prior to the discovery of the genetic cause of HI, prenatal diagnostic investigations depended  
on obtaining a foetal biopsy for analysis by electron microscopy, and on sonography [33,34]  
(reviewed in [35]). The discovery of the genetic cause of different ichthyoses, including HI, represents 
a major milestone in the ability to perform genetic diagnosis, carrier screening, genetic counselling, 
and prenatal diagnosis. 
Current approaches to genetic screening for HI can involve screening specific exons, as there are 
some recurrent ethnic group mutations in ABCA12 [18,19] and using WES, circumventing the need for 
performing PCR and Sanger sequencing of all 53 coding exons of the ABCA12 gene. 
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3. Exfoliative Ichthyosis 
The discovery of cystatin A (CSTA) gene mutations in association with exfoliative ichthyosis [36] is 
an example of the successful implementation of combining SNP microarray analysis with targeted 
NGS to determine the genetic cause of disease. 
Autosomal recessive exfoliative ichthyosis (OMIM #607936) is characterised by palmoplantar skin 
peeling and dry scaly skin, with trauma and moisture aggravating the condition [36]. Microsatellite 
linkage analysis of two related Bedouin families initially suggested linkage of the disease to chromosome 
12q13, which contains the type II keratin cluster [37]. 
Blaydon et al. (2011) [36] revisited this family and applied whole genome homozygosity mapping 
which revealed a common block of homozygosity between affected Bedouin patients on chromosome 
3q21 as the likely disease gene location. Sequence capture and NGS of this region was then performed 
and revealed a splice site mutation in CSTA, which was found to segregate with exfoliative ichthyosis 
in the Bedouin family. This locus was missed in the microsatellite genome scans performed by  
Hatsell et al. (2003) [37] due to markers for this region being uninformative. Sanger sequencing of 
CSTA in a different family with exfoliative ichthyosis revealed a homozygous nonsense mutation 
which also segregated with disease [36]. In a subsequent study, WES revealed a novel homozygous 
nonsense mutation in CSTA in a large family with acral peeling skin syndrome [38] with similar 
clinical features to the patients reported in Blaydon et al. (2011) [36]. 
Cystatins are cysteine protease inhibitors which are thought to have a protective function against 
endogenous and external proteases, and to potentially modulate the degradation of intra- and extracellular 
proteins (reviewed in [39]). CSTA has been identified as a constituent of the cornified envelope [40] 
and is expressed in the suprabasal layers of the epidermis, the highest expression of which is in the 
granular layer [36,41]. CSTA is secreted by keratinocytes in vitro and has also been found in sweat, 
and is believed to have a protective role by inhibiting the proteolytic activity of dust mite allergens  
Der p 1 and Der f 1 [42]. CSTA levels have also been implicated as prognostic markers in different 
cancers [43–45]. 
Characterisation of skin from exfoliative ichthyosis patients with CSTA mutations revealed widened 
intercellular gaps in the lower epidermis, whereas the upper epidermal layers appeared normal with  
no evident barrier defect [36]. Experiments using an in vitro keratinocyte cell knockdown model 
showed an adhesion defect in response to mechanical stress, and an organotypic CSTA knockdown 
model showed similar abnormalities to the patient skin [36]. This finding is indicative of CSTA having 
a key role in keratinocyte adhesion in the basal epidermal layers and that loss of CSTA causes a 
predisposition to epidermal splitting. There were no obvious abnormalities in a murine model with a 
chromosomal deletion, which included the Csta gene [46], although investigation of a skin phenotype 
was not described. 
4. Olmsted Syndrome 
The genetic basis of various skin diseases (Table 1) has been determined using exome sequencing 
technology. One example where WES enabled the identification of the underlying causative genes  
is Olmsted syndrome (OS) [47,48]. OS (OMIM #614594) is a rare disorder characterised by mutilating 
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palmoplantar keratoderma and periorificial keratosis. Additional clinical features include constriction 
of the digits, dystrophy of the nails, diffuse alopecia and a predisposition to infection and development 
of squamous cell carcinoma on keratotic lesions [47]. Different modes of inheritance have been 
hypothesised [47–50]. 
Table 1. Examples of genes associated with skin disease discovered using exome 
sequencing technology. 
Gene Disease Mode of Inheritance Reference 
AAGAB Punctate palmoplantar keratoderma Type I AD [51,52] 
ADAM10 Reticulate acropigmentation of Kitamura AD [53] 
AQP5 Nonepidermolytic palmoplantar keratoderma AD [54] 
ENPP1 Cole disease AD [55] 
EXPH5 Inherited skin fragility AR [56] 
HOXC13 Pure hair and nail ectodermal dysplasia AR [57] 
KANK2 Palmoplantar keratoderma and woolly hair AR [58] 
MBTPS2 Olmsted syndrome XLR [48] 
POFUT1 Dowling-Degos disease AD [59] 
POGLUT1 Dowling-Degos disease AD [60] 
SERPINB7 Nagashima-type palmoplantar keratosis AR [61] 
TRPV3 Olmsted syndrome AD/AR [47]/[62] 
AD: autosomal dominant; AR: autosomal recessive; XLR: X-linked recessive. 
WES was used successfully to identify mutations in the Transient Receptor Potential Cation Channel, 
Subfamily V, Member 3 (TRPV3) gene [47], and the Membrane-Bound Transcription Factor Protease, 
Site 2 (MBTPS2) gene [48] to be associated with OS. 
Lin et al. (2012) performed WES of an OS patient and her unaffected parents and identified a novel 
de novo heterozygous mutation p.G573S in TRPV3 [47]. Screening for TRPV3 mutations in five other 
OS patients revealed that three were heterozygous for p.G573S, one heterozygous for p.G573C and 
one heterozygous for p.W692G [47]. 
TRPV3 is a member of the TRPV cation channel family, and is known to be expressed in various 
tissue types including skin and hair follicles [63–65]. The murine TRPV3 mutants p.G573S and p.G573C 
were discovered in spontaneous hairless rodent strains that develop dermatitis, a trait inherited in an 
autosomal dominant manner [66]. Trpv3 knockout mice display wavy hair, curly whiskers and a defective 
skin barrier, and it is believed that TRPV3 associates with TGF-α/EGFR in a signalling pathway to 
modulate keratinocyte differentiation and hair morphogenesis [67]. 
In vitro functional studies with the three OS-associated TRPV3 mutants indicated that they are gain 
of function mutants, creating constitutively open channels and causing increased cell death of cells 
expressing the mutants [47]. Similar results were obtained in in vitro expression studies with the murine 
TRPV3 mutants p.G573S and p.G573C [68]. It has been hypothesised that in vivo the mutants may 
cause apoptosis and subsequent keratoderma in patients, and could contribute to their pruritis [47]. 
A subsequent study using WES revealed the recurrent TRPV3 mutation p.G573S in sporadic  
OS [69]. Screening by Sanger sequencing has also revealed a homozygous mutation in an OS patient, 
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indicating recessive inheritance [62]. Both recessive [70] and sporadic [71] TRPV3 mutations have 
been associated with atypical OS with erythromelalgia. 
Exome sequencing of two affected males reported previously in a consanguineous pedigree [72]  
in which OS followed a suggested X-linked recessive inheritance pattern, revealed a novel MBTPS2 
gene mutation which segregated with disease in the family [48]. This discovery expands the number of 
disorders attributed to MBTPS2 gene mutations, as other mutations in this gene are associated with 
ichthyosis follicularis with atrichia and photophobia (IFAP) syndrome [73–75], BRESEK/BRESHECK 
syndrome [76], and keratosis follicularis spinulosa decalvans (KFSD) [77]. 
MBTPS1 and MBTPS2 are involved in activating signalling proteins such as the transcription 
factors SREBPS, enabling cells to respond to sterols [78,79] and in the processing of ATF6, which is  
a component of the unfolded protein response (UPR) [80]. In vitro functional studies with IFAP and 
KFSD MBTPS2 mutants revealed decreased sterol responsiveness compared to wild-type [73,77], and 
mutants which caused the greatest impairment of enzyme activity seemed to be associated with 
increased disease severity in patients [73]. 
5. Complex Traits of the Skin 
In the last 10 years there have been landmark discoveries in our understanding of the genetic basis 
and pathophysiology of inflammatory skin diseases, most notably PV and AD. Both are common, 
complex diseases, in which a host of environmental factors can trigger disease in genetically susceptible 
individuals [81,82]. Inflammatory dermatoses are associated with both a significant burden on healthcare 
resources and patients’ quality of life [83,84]. 
Identification of susceptibility loci for PV and AD have resulted from developments in genome 
wide association studies (GWAS), which have been applied to all common disorders. Information  
has been generated by the HapMap and 1000 Genomes projects, in parallel with the technology to 
genotype multiple individual DNA samples at one million or more loci, allowing SNPs to be reviewed 
and enabling comparisons of allele frequency between large numbers of cases and controls to identify 
those which confer risk of disease [85]. The development of DNA microarray based genotyping allows 
up to a million SNPs to be tested simultaneously. 
6. Psoriasis 
PV is a common and chronic inflammatory disease, which can affect the skin, nails and joints.  
It is characterised by immune-mediated epidermal hyperproliferation [86]. It is a highly heritable 
disease, with increased concordance in monozygotic versus dizygotic twins (65%–72% versus 15%–30% 
respectively) [87]. During the last 10 years, almost 40 GWAS-identified novel psoriasis-susceptibility 
loci have been identified and more recently, the genes within these loci and their significance to the 
pathophysiology of PV are becoming clearer [88]. Interestingly, several show clustering to a distinct 
segment of the inflammatory cascade [89]. Psoriasis susceptibility locus 1 (PSORS1), located on  
the MHC region on chromosome 6p21, has been most consistently identified in GWAS with a  
significant odds ratio of 3.0 [90]. Genes implicated within this 250 kb interval include HLA-C (human  
leukocyte antigen C), CCHCR1 (coiled-coil α-helical rod protein 1), and CDSN (corneodesmosin). 
These were considered as potential disease-associated genes due to their function and the presence  
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of disease-associated SNPs within their coding sequence [91]. Identification of the causal disease 
susceptibility allele was extremely challenging, ultimately Nair et al. (2006) sequenced the entire 
PSORS1 region in individuals bearing different HLA-C alleles to identify SNPs unique to the PSORS1 
haplotype. They indicated that HLA-Cw6 was the major PSORS1 disease allele [92], reflecting the 
importance of antigen presentation in the pathophysiology of PV. 
Identification of susceptibility loci has contributed to our understanding of PV pathogenesis, which 
appears to involve the innate and adaptive immune responses. Pathways that have been identified in 
various studies include IL12/IL17 axis activation (IL23R, IL12B, IL23A, and TRAF31P2), type 1 
interferon induction (IFIH1, RNF114, and TYK2) and NF-κB signaling (CARD14, REL, NFKBIA, 
TNFAIP3, and TNF1P) [89,90,92–97]. Of particular interest is the Th1-Th17 axis, involving the recently 
described subset of IL17 expressing T cells (Th17) [98] which is thought to play a major role in the 
development and maintenance of psoriatic plaques [97]. 
IL12 and IL23 are cytokines that induce naïve CD4
+
 lymphocytes to differentiate into type 1 helper 
cells and type 17 helper cells, both of which are key mediators of PV [97]. IL12 and IL23 share a common 
p40 subunit encoded by the IL12B gene. In mice, injection of IL23 results in epidermal hyperplasia, 
which is mediated by IL22 produced by Th17 cells. This shows similarities to phenomena observed in 
humans [99]. GWAS have identified three SNPs with strong evidence of association with PV mapping 
near IL12B, IL23A (encoding the p19 subunit of IL23) and IL23R (encoding a subunit of the IL23 
receptor) [94] raising the possibility that dysregulated IL23 signaling could lead to chronic immune 
responses within epithelial cells. Ustekinumab (Stelara
®
) is a human IgG1κ monoclonal antibody 
against the p40 subunit of the IL12 and IL23 cytokines that has demonstrated significant improvement 
in outcome measures for the treatment of PV in Phase III clinical trials [100]. A significant proportion 
of patients had at least 90% improvement in their psoriasis area-and-severity index (PASI) score,  
with a proportion experiencing complete clearance by 12 weeks [100]. These findings also establish a 
central role for the IL12/IL23 p40 cytokines in the pathophysiology of PV. 
Another approach to utilise the discoveries gained from GWAS studies is personalised medicine. 
For example, patients with PV who carry risk variants in IL12B may benefit preferably from a 
monoclonal antibody targeting its p40 subunit, e.g., Ustekinumab. Studies using molecular profiling of 
PV and clinical phenotyping to predict treatment response have shown promise [101] and larger studies 
are underway. This is one example of how PV has been used as a paradigm for autoimmune disease 
and for proof-of-principle studies of targeted biologic therapies, because of the ease of accessing the 
skin and objectively measuring disease severity and responses to treatment. 
Rare variants with large effect have been observed in families where PV segregates as an apparent 
Mendelian trait. The psoriasis susceptibility locus 2 (PSORS2) was first mapped in 1994 to human 
chromosomal region 17q25-qter in a large family of European ancestry [102]. More recently, it has 
been shown that PSORS2 is due to gain of function mutations in the caspase recruitment domain 
family member 14 (CARD14) [96] using linkage analysis, targeted and exome capture in combination 
with NGS. On the basis of these findings, further work has uncovered rare missense variations in CARD14 
linked to PV using a large case-control study [95]. CARD14 encodes a NF-κB activator within the skin 
epidermis. The mutations identified lie within the coiled-coiled domain of CARD14 and result in 
enhanced NF-κB activity compared with wild-type CARD14 [95]. 
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Generalised pustular psoriasis (GPP) can present with an acute, widespread and life-threatening 
eruption associated with fever and leukocytosis. It has long been considered a variant of PV. Mutations 
in IL36RN, which encodes the IL36 receptor antagonist and abrogates downstream activation of  
NF-κB signaling, have been shown to underlie GPP in consanguineous pedigrees of North African 
origin [103]. This mutation results in enhanced production of IL1, IL6, and IL8 inflammatory cytokines, 
which may contribute to the profound systemic inflammatory response seen clinically in these  
patients [103]. Similar recessive mutations in IL36RN have not been observed in patients with PV 
alone [104]. Genetic studies suggest that in fact, PV and GPP are etiologically distinct clinical entities, 
which consequently have important therapeutic implications [105]. 
7. Atopic Dermatitis (Eczema) 
AD is a chronic inflammatory skin disease characterised by disturbed skin barrier function and  
dry, itchy skin. Its prevalence worldwide is increasing and in some countries affects almost 20% of  
children [106]. Like PV, concordance is observed in twin studies with rates of 0.72–0.86 in monozygotic 
and 0.21–0.23 in dizygotic twin pairs [107]. A complex interplay between environmental, genetic and 
immunological factors, as for many common disorders, all contribute to susceptibility and severity. 
The filaggrin story is central to our understanding of AD and ichthyosis vulgaris (IV). It exemplifies 
how the study of a monogenic disorder can translate to a complex trait disease. In 2006, null mutations 
in the filaggrin gene FLG were first identified in Irish families with IV, which often causes dry, scaly 
skin and is also a strong genetic risk factor for AD [108]. Histological evidence for the possible lack  
of filaggrin in IV dates back to 1985 [109] however these preliminary studies were hindered by  
the daunting size and repetitive nature of FLG, particularly exon 3. The McLean group developed a 
successful strategy to analyse this locus with the use of long range PCR to amplify exon 3 in combination 
with short specific PCRs to amplify remaining overlapping fragments that were then used to reconstruct 
the repetitive sequence [108]. Further research has identified significant associations of FLG mutations 
with atopic asthma, allergic rhinitis and peanut allergy [110], as well as early onset and increased 
severity of AD [111]. These studies have been reproduced in a variety of geographical populations, 
including European, Japanese, Taiwanese, Chinese, and Korean [112–114]. Indeed, the correlation 
between FLG mutations and AD is considered one of the most robust examples of genotype-phenotype 
relationship in complex trait disease with an odds ratio of up to 13.4 [115]. 
Filaggrin plays a key role in epidermal barrier function. Briefly, its degradation products act  
as ―natural moisturising factors‖ in the skin and assist the formation of a flattened granular cell  
layer upon keratinocyte terminal differentiation [116]. Studies describing murine models of filaggrin 
haploinsufficiency have shown skin barrier impairment and enhanced sensitisation to percutaneous 
allergens [117,118]. The significant effect of FLG mutations on AD risk highlights the role of impaired 
skin barrier function in the pathogenesis of atopic diseases. Filaggrin replacement therapies could 
prove significant in the management of AD. Recently, Otsuka et al. (2014) [119] identified a novel 
compound JTC801, with potential therapeutic applicability. This has been shown to increase expression 
of filaggrin in both human and murine keratinocytes and, when administered orally, it can hinder the 
development of AD-like inflammation in the NC/nga AD mouse model [119]. 
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Although the AD spotlight has focused largely on filaggrin, several other genes have been implicated 
in the pathogenesis of this disorder. To date, a total of 19 genome-wide significant (p < 5 × 10
−8
) 
susceptibility loci have been identified through GWAS [120]. The first GWAS data was published  
in 2009 and included 939 cases and 975 controls in addition to 270 complete nuclear families with  
two affected siblings [121]. It identified a novel susceptibility locus in 11q13.5, located 38 kb downstream 
of C11orf30. The peak association was observed 68 kb upstream of the leucine rich repeat containing 
32 gene (LRRC32) which has been shown to be expressed in activated human regulatory T cells [122]. 
Carriers have a risk of developing AD that is 1.47 times that of controls [121]. A 2011 Meta analysis 
of GWAS for AD included 5606 cases and 20565 controls and an additional 5419 cases and 19833 controls 
in a validation study [114]. Three novel risk loci reached genome-wide significance: rs479844 upstream 
of ovo-like zinc finger 1 (OVOL1), rs2164983 near actin-like 9 (ACTL9) and rs2897442 in kinesin 
family member 3A (KIF3A). They also confirmed association with the FLG locus. OVOL1 disruption 
in mice leads to keratinocyte hyperproliferation and hair shaft abnormalities [93]. It is thought to play  
a role in regulating epidermal proliferation and loricrin expression, impairing premature terminal 
differentiation [123]. KIF3A associated SNPs map within a cluster of cytokine and immune mediated 
genes including Th2 cytokine genes: IL13 and IL4. These cytokines have been implicated in other 
autoimmune and inflammatory diseases including PV [124], Crohn’s Disease [125] and asthma [125]. 
Increased levels of Th2 cytokines such as these have been reported in AD as well as greater levels  
of mRNA expression in acute skin lesions compared with unaffected skin in patients [126–128].  
These GWAS findings highlight the role of skin barrier function (FLG), epidermal proliferation and 
differentiation (OVOL1) and the adaptive immune system response (IL13-RAD50, LRRC32) in the 
pathophysiology of AD. 
Despite these promising discoveries, less than 20% of disease variance has been explained [129]. 
The phenomenon of ―missing heritability‖ has been observed across other complex diseases and suggests 
that unmapped common and rare variants with small effect size in GWAS as well as genetic interactions 
may contribute to the remaining heritability [129]. Epigenetic studies focusing on the contribution of 
DNA and chromatin methylation may also explain the role that they play in the formation and progression 
of complex diseases by regulating gene expression [130]. Future work integrating GWAS and epigenetic 
data may provide insights into our understanding of complex trait disease. In summary, GWAS data 
reinforces the concept that multiple low risk variants are most likely to contribute to AD and PV, but 
that larger sample sizes may be necessary to identify them. 
8. Conclusions 
The post-Human Genome Project era has seen remarkable advances in our understanding of  
genes underlying both rare and common skin disease. Such insights have proved significant beyond 
the field of dermatology because of shared mechanisms of disease for example, PV and inflammatory 
bowel disease. The wider relevance of skin disease is highlighted by the fact that skin is frequently  
a marker of internal disease. For example, mutations in ADAM17 not only cause inflammatory skin  
and bowel disease but increased susceptibility to infection and cardiomyopathy [131]. Similarly, the 
study of tylosis with oesophageal cancer, an autosomal dominant cancer syndrome that presents with 
skin thickening of the palms and soles, has brought to light the role of the inactive rhomboid family 
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member iRHOM2 in cancer pathophysiology [132] and wound healing [133]. This also highlights  
that mechanistic studies are facilitated by the relative ease with which patient material can be obtained 
by skin biopsy to derive cell lines for functional studies. 
Skin disease is particularly remarkable for its intragenic heterogeneity, for example distinct 
dominant and recessive mutations in the desmosomal Desmoplakin gene DSP can result in a spectrum 
of disease phenotypes ranging from arrhythmogenic right ventricular cardiomyopathy (ARVC) and 
striate palmoplantar keratoderma to palmoplantar keratoderma with woolly hair and ARVC (reviewed 
in [134]). 
GWAS, WES and whole genome sequencing (WGS) involving increasingly larger cohorts of ethnically 
diverse populations may also identify additional low and high penetrance variants that contribute to 
phenotypic variability. WGS is becoming increasingly affordable and offers scope to become the most 
cost-effective method for genetic diagnostics. In parallel, advances in bioinformatics and statistics are 
necessary to analyse the vast quantity of data generated by these studies, and distinguish significant 
findings. We may also see a move towards re-classification of skin diseases and malignancies based on 
genome sequence and subsequently, a targeted therapeutic approach to optimise treatment outcome. 
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